Rituximab (Rituxan) is a biologic agent used to deal with individuals with rheumatoid arthritis (RA) who have failed at least 1 TNF inhibitor this kind of as Enbrel, Humira, and Remicade.

It is an antibody which combines protein components from a mouse and protein components from a human. This antibody is directed in opposition to certain kinds of cells called B cells. Not all B cells are impacted. Only B cells that have a marker known as CD 20 are targeted. When Rituxan is given B cells with the CD 20 marker are eliminated from the circulation.

Rituxan is not a new drug. It has been used extensively for some time in patients with non-Hodgkins lymphoma. Rituxan was approved by the FDA in 2006 for use in RA.

Several big trials have demonstrated Rituxan’s effectiveness in both clinical and x-ray outcomes, especially in individuals who formerly have had inadequate reaction to oral disease modifying medications (DMARDS) such as methotrexate and TNF inhibitor therapy.

Individuals who are good for rheumatoid factor (RF) appear to react better than RF unfavorable patients.

While CD twenty lymphocytes are nearly totally removed from the method, it appears that immunoglobulins (the antibodies that are usually produced by lymphocytes to fight infections and tumors) are not depleted.

This is important from the viewpoint of permitting a person’s natural immunity to not be adversely affected.

Rituxan is given intravenously. The initial dose is administered over an eight hour period. The next dose is administered two weeks later more than about 5-six hours. Patients usually do not need another infusion (intravenous dose) for at minimum 6 months and sometimes lengthier.

The most common aspect effects of Rituxan infusion have been itching, fever, rash, hives, chills, sneezing, swelling of the encounter, throat irritation, cough and shortness of breath, reduced blood pressure, and higher blood stress all of which are more most likely to happen with the initial infusion of the drug.

Premedication with intravenous methylprednisolone (Solumedrol), acetaminophen, and diphenhydramine (Benadryl) can considerably decrease the incidence of infusion reactions.

In one of the major clinical trials, the REFLEX study, the price of serious infections was 5.two for each 100 patient-many years with Rituxan in contrast to three.seven per 100 affected person-years with placebo.

Whilst the risk of infection with Rituxan is reduced, there remains a problem simply because of reports of severe reactivation of chronic viral infections after Rituxan treatment. Patients with chronic hepatitis B and other viral infections ought to not obtain Rituxan unless of course completely essential.

Also, the FDA lately issued a community well being advisory alert for Rituxan based on 2 uncommon situation reports of patients with systemic lupus erythematosus in whom progressive multifocal leukoencephalopathy, a very uncommon but inevitably fatal central nervous system disorder, developed after getting the drug. No instances of progressive multifocal leukoencephalopathy have been noted in patients with RA who had been treated with Rituxan.

So far, the effectiveness and safety profile of Rituxan are encouraging. Further adhere to-up and much more clinical research are nonetheless required.

for more resources and information on clinical trial packaging and  cold chain management and  cold chain technologies please see our website